scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
76 hedge funds and large institutions have $134M invested in scPharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 15 closing their positions.
380% more call options, than puts
Call options by funds: $753K | Put options by funds: $157K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.85% less ownership
Funds ownership: 78.02% → 74.17% (-3.8%)
6% less funds holding
Funds holding: 81 → 76 (-5)
14% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 29
23% less capital invested
Capital invested by funds: $175M → $134M (-$41.2M)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.45M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.58M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.12M |
| 5 |
Renaissance Technologies
New York
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$4.31M |
| 2 |
SC
Stempoint Capital
New York
|
-$3.56M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$3.13M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$1.6M |
| 5 |
Walleye Capital
New York
|
-$1.58M |
SCPH Hedge Fund Activity: Q1 2024 in Review
76 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2024, worth a combined $134M — down 23% from $175M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SCPH and 10 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 25 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $2.5M. The largest seller was Worth Venture Partners, cutting an estimated $4.31M.
- 76 institutional investors held scPharmaceuticals (SCPH) as of Q1 2024, down from 81 in Q4 2023.
- Funds reported $134M of scPharmaceuticals stock for Q1 2024, down 23% quarter-over-quarter.
- 10 funds opened new scPharmaceuticals positions in Q1 2024 and 15 closed out, a net change of -5 holders.
- The largest scPharmaceuticals buyer in Q1 2024 was Stonepine Capital Management, an estimated $2.5M added.
- The largest scPharmaceuticals seller in Q1 2024 was Worth Venture Partners, an estimated $4.31M sold.
Based on aggregated 13F filings for Q1 2024.